2 registrations that name lumbrokinase as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT06511050
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Phase 1 and 2
Icahn School of Medicine at Mount Sinai
About 120 people
Started Oct 9, 2024
In plain words A Phase 1 and 2 study of lumbrokinase in people 18 and older, run by Icahn School of Medicine at Mount Sinai. It plans to enroll about 120 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Long Covid; Post-treatment Lyme Disease Syndrome; Chronic Fatigue Syndrome; Myalgic Encephalomyelitis.
Any gender
Aged 18+
Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected as part of the baseline survey).
Diagnosed with only one of the following conditions:
28 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Lumbrokinase
Registered summary
This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts: * Long Covid (LC) * Post-treatment Lyme disease syndrome (PTLDS) * Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07763405
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke
Phase 4
Xinqiao Hospital of Chongqing
About 1,196 people
Starts Nov 1, 2026 (estimated)
In plain words A Phase 4 study of lumbrokinase in people 18 to 80, run by Xinqiao Hospital of Chongqing. It plans to enroll about 1,196 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Ischemic Stroke, Acute.
Age 18-80 years;
Acute ischemic stroke confirmed by CT or MRI;
Baseline NIHSS score 4-20 at enrollment;
Good prestroke functional status (mRS ≤1);
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Lumbrokinase; Lumbrokinase Placebo
Registered summary
LUMEN is a multicenter, randomized, double-blind, placebo-controlled superiority trial designed to evaluate whether oral lumbrokinase enteric-coated capsules combined with aspirin improve functional outcomes compared with aspirin alone in patients with moderate-to-severe acute ischemic stroke. The full summary is on the listing.